ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with about 1 in 8 women being diagnosed in their lifetime.[1] It also accounts for nearly 30% of all new female cancer diagnoses each year, with Read More
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the Article
News
Media Releases
Agendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read MoreAgendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read MoreAgendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read MoreMammaPrint® approved for Reimbursement in the Netherlands
The Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the Dutch National health insurance basic package with immediate effect.
Read More